In the last trading session, 1.79 million shares of the CytomX Therapeutics Inc (NASDAQ:CTMX) were traded, and its beta was 1.05. Most recently the company’s share price was $0.86, and it changed around -$0.05 or -5.14% from the last close, which brings the market valuation of the company to $61.48M. CTMX currently trades at a discount to its 52-week high of $5.85, offering almost -580.23% off that amount. The share price’s 52-week low was $0.91, which indicates that the current value has fallen by an impressive -5.81% since then. We note from CytomX Therapeutics Inc’s average daily trading volume that its 10-day average is 1.32 million shares, with the 3-month average coming to 780.28K.
CytomX Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 9 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 3 recommended CTMX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. CytomX Therapeutics Inc is expected to report earnings per share of -0.12 for the current quarter.
CytomX Therapeutics Inc (NASDAQ:CTMX) trade information
Instantly CTMX has showed a red trend with a performance of -5.14% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.0750 on recent trading dayincreased the stock’s daily price by 20.0%. The company’s shares are currently down -44.31% year-to-date, but still down -17.00% over the last five days. On the other hand, CytomX Therapeutics Inc (NASDAQ:CTMX) is -26.85% down in the 30-day period. We can see from the shorts that 5.67 million shares have been sold at a short interest cover period of 9.58 day(s).
The consensus price target as assigned by Wall Street analysts is $5.84, which translates to bulls needing to increase their stock price by 85.27% from its current value. Analyst projections state that CTMX is forecast to be at a low of $3.25 and a high of $8.
CytomX Therapeutics Inc (CTMX) estimates and forecasts
CytomX Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -55.04 percent over the past six months and at a -1,200.00% annual growth rate that is well below the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -1,310.00% in revenue this quarter, and will report a decrease of -111.76% in the next quarter. The year-over-year growth rate is expected to be 12.12%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 13.53M in revenue for the current quarter. 3 analysts expect CytomX Therapeutics Inc to make 18.5M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 26.61M and 41.46M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -49.14%. Forecasts for the next quarter put sales growth at -55.38%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 67.21%. CytomX Therapeutics Inc earnings are expected to increase by -881.57% in 2024, but the outlook is negative -0.90% per year for the next five years.
CTMX Dividends
CytomX Therapeutics Inc’s next quarterly earnings report is expected to be released in December.
CytomX Therapeutics Inc (NASDAQ:CTMX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.00% of CytomX Therapeutics Inc shares, and 65.20% of them are in the hands of institutional investors. The stock currently has a share float of 65.86%. CytomX Therapeutics Inc stock is held by 80.0 institutions, with TANG CAPITAL MANAGEMENT LLC being the largest institutional investor. By 2024-06-30, it held 9.4989% of the shares, which is about 7.79 million shares worth $9.51 million.
JANUS HENDERSON GROUP PLC, with 7.6826% or 6.3 million shares worth $7.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
